MassVentures Invests in Curoverse to Accelerate Development of Open Source Biomedical Big Data Platform

MassVentures today announced its investment in Curoverse.  Curoverse has raised $1.5 million to accelerate commercial development of the Arvados open source platform for genomic and biomedical big data and bring to market products and services based on the platform.

Arvados was released as a free and open source project in April 2013 at http://arvados.org. Today, the Arvados software powers a private cloud with 300 TB of storage and 500 cores that is used for genomic analysis at the Harvard Personal Genome Project and for research work at Harvard Medical School. The platform includes a content addressable distributed storage system and a computational management system designed to make complex analyses easily reproducible.

“MassVentures is pleased to see this type of large scale, big data IT opportunity pursued here in the state,” adds Jennifer Jordan, Vice President, MassVentures. “Curoverse has an opportunity to further Massachusetts’ leadership in biomedicine, bringing customers a unique solution to address the big data infrastructure needs of their biomedical research and clinical applications.”

For the complete Curoverse press release please click here.